Letrozole Monotherapy. NCCP National SACT Regimen. HSE.

Regulatory approval published by the Health Service Executive.

Citation

Letrozole Monotherapy, 2020, version number 3, NCCP National SACT Regimen, NCCP, viewed 21/07/2024, https://www.hse.ie/eng/services/list/5/cancer/profinfo/chemoprotocols/breast/371.pdf

View API

Regulatory approvals

Approved indications from this document for cancer drugs containing at least one biomarker.

Indication Statements
Adjuvant treatment of postmenopausal women with hormone receptor positive invasive early breast cancer. 3
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer. 3
Extended adjuvant treatment of hormone-dependent-invasive breast cancer in postmenopausal women who have received prior adjuvant endocrine therapy for 5 years. 3
Neo-adjuvant treatment of postmenopausal women with hormone receptor positive breast cancer. 3

Therapeutic response

Precision oncology relationships for therapeutic response derived from this document.

Type Biomarker(s) Cancer type Therapy(ies)
Sensitivity (+) ER positive, PR positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) ER positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) PR positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) ER positive, PR positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) ER positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) PR positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) ER positive, PR positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) ER positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) PR positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) ER positive, PR positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) ER positive Invasive Breast Carcinoma Letrozole
Sensitivity (+) PR positive Invasive Breast Carcinoma Letrozole